SAN DIEGO, Sept. 27, 2017 /PRNewswire/ -- Qualcomm Incorporated (NASDAQ:QCOM), through its wholly owned subsidiary, Qualcomm
"This wearable patch technology will be transformative in its ability to provide timely and accurate data to enable care providers to make better-informed decisions," said James Mault, MD, FACS, senior vice president and Chief Medical Officer, Qualcomm Life. "Utilizing Qualcomm's 30 years of leadership in inventing new connected "things," this low-power, cost-effective, single-use design will fuel new, scalable care models as we transition as an industry from episodic, reactive care to more continuous, proactive, intelligent care."
As a part of the collaboration, Qualcomm Incorporated, Qualcomm Life, Inc. and Benchmark Electronics entered into a Healthcare Product License Agreement, which allows Benchmark to license reference designs for Qualcomm Life's biometric patches. Clinical validation is currently underway, and the patches are slated to be commercially available through Benchmark in 2018.
"We are thrilled to work with Qualcomm Life, a global leader in inventing revolutionary connected technologies, to create a new packaged sensor offering for health care companies that is economical, secure and user friendly," said Paul Tufano, CEO, Benchmark Electronics. "This collaboration aligns with our mission to deliver high-value solutions and innovative technology for our customers."
The innovative, cost-effective patches were developed on Qualcomm Life's 2net™ Design platform, a reference design platform for electronics modules which power connected medical devices, including disposable drug delivery devices and disposable diagnostic devices. 2net Design leverages Qualcomm's expertise in developing innovative reference designs for wireless, power-efficient, small-integrated modules to create smarter, more affordable and intuitive medical devices.
Qualcomm's technologies powered the smartphone revolution and connected billions of people. We pioneered 3G and 4G – and now we are leading the way to 5G and a new era of intelligent, connected devices. Our products are revolutionizing industries, including automotive, computing, IoT, healthcare and data center, and are allowing millions of devices to connect with each other in ways never before imagined. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, all of our engineering, research and development functions, and all of our products and services businesses, including, our QCT semiconductor business. For more information, visit Qualcomm's website, OnQ blog, Twitter and Facebook pages.
About Benchmark Electronics, Inc.
Benchmark provides worldwide integrated electronics manufacturing services (EMS), engineering and design services, and precision machining services to original equipment manufacturers in the following industries: industrial controls, aerospace and defense, telecommunications, computers and related products for business enterprises, medical devices, and test and instrumentation. Benchmark's global operations include facilities in seven countries, and its common shares trade on the New York Stock Exchange under the symbol BHE.
2net is a product of Qualcomm Life, Inc.
2net is a trademark of Qualcomm Incorporated, registered in the United States and other countries.
Qualcomm Contacts:Pete Lancia Corporate CommunicationsPhone: 1-858-845-5959Email: firstname.lastname@example.org
John Sinnott, Investor RelationsPhone: 1-858-658-4813Email: email@example.com
View original content:http://www.prnewswire.com/news-releases/qualcomm-invents-new-smart-single-use-biometric-patches-300526432.html
SOURCE Qualcomm Incorporated
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All